PMID- 20450761
OWN - NLM
STAT- MEDLINE
DCOM- 20110404
LR  - 20160818
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 39
IP  - 3
DP  - 2010 Mar
TI  - [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by 
      dual-probe chromogenic in situ hybridization and fluorescence in situ 
      hybridization].
PG  - 161-5
AB  - OBJECTIVE: To evaluate the application of dual-probe chromogenic in situ 
      hybridization (dual-probe CISH) in analysis of HER2 gene status of breast cancer 
      patients by comparison with fluorescence in situ hybridization (FISH). The 
      potential impact of chromosome 17 polysomy in the determination of HER2 status 
      was also studied. METHODS: One hundred and forty-six cases of paraffin-embedded 
      breast cancer tissues were retrieved. Analysis of HER2 gene and chromosome 17 
      copy numbers using CE-approved commercial kits of dual-probe FISH (for 146 cases) 
      and dual-probe CISH (for 73 cases) were carried out. The results were interpreted 
      according to ASCO/CAP, 2007 either HER2 gene copy number or the ratio of 
      HER2/centromere 17 (CEN17). RESULTS: Of the 73 cases analyzed by both FISH and 
      dual-probe CISH, the concordance rates for negative and positive results was 
      91.7% (33/36) and 97.4% (37/38) respectively, while the overall concordance rate 
      between the two methods was 95.9% (70/73). Of the 146 cases analyzed by FISH, 13 
      cases were interpreted as equivocal if only HER2 copies were counted, compared 
      with 8 equivocal cases by calculating the ratio of HER2/CEN 17. Moreover, 3 cases 
      (4.8%) of the 63 HER2-positive cases determined by HER2 copies turned out to be 
      HER2-negative when determined by the ratio of HER2/CEN 17; while using dual-probe 
      CISH, 1 (3.0%) of the 33 positive cases turned out to be negative. In addition, 
      when using FISH, there were more chromosome 17 polysomy cases (63.5%, 40/63) in 
      the HER2-positive subgroup than HER2-negative subgroup (37.3%, 28/75) (P = 
      0.002). CONCLUSIONS: Dual-probe CISH can achieve similar results as compared to 
      FISH, indicating that this technology is a reliable alternative to FISH in HER2 
      testing. The accuracy can further be improved when HER2 and chromosome 17 are 
      simultaneously tested and counted.
FAU - Bai, Yan-feng
AU  - Bai YF
AD  - Department of Pathology, the First Affiliated Hospital, College of Medicine of 
      Zhejiang University, Hangzhou 310003, China.
FAU - Ren, Guo-ping
AU  - Ren GP
FAU - Wang, Bo
AU  - Wang B
FAU - Teng, Li-song
AU  - Teng LS
FAU - Liu, Xu
AU  - Liu X
LA  - chi
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
SB  - IM
MH  - Breast Neoplasms/*genetics
MH  - Carcinoma, Ductal, Breast/*genetics
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Gene Dosage
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - In Situ Hybridization/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Paraffin Embedding
MH  - Polyploidy
EDAT- 2010/05/11 06:00
MHDA- 2011/04/05 06:00
CRDT- 2010/05/11 06:00
PHST- 2010/05/11 06:00 [entrez]
PHST- 2010/05/11 06:00 [pubmed]
PHST- 2011/04/05 06:00 [medline]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2010 Mar;39(3):161-5.